Provided by Tiger Fintech (Singapore) Pte. Ltd.

MoonLake Immunotherapeutics

42.32
+0.88002.12%
Post-market: 42.320.00000.00%16:05 EDT
Volume:367.38K
Turnover:15.56M
Market Cap:2.68B
PE:-22.37
High:42.90
Open:41.74
Low:39.86
Close:41.44
Loading ...

MoonLake Immunotherap Price Target Maintained With a $66.00/Share by Needham

Dow Jones
·
30 Apr

Is MoonLake Immunotherapeutics (MLTX) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

Insider Monkey
·
24 Apr

MoonLake Obtains $500 Million Facility From Hercules Capital

MT Newswires Live
·
03 Apr

BRIEF-Moonlake Secures Up To $500 Million In Non-Dilutive Financing From Hercules Capital And Announces A Capital Markets Update On April 29 To Provide Important Clinical Updates

Reuters
·
03 Apr

MoonLake Immunotherapeutics secures up to $500M in non-dilutive financing

TIPRANKS
·
03 Apr

MoonLake Secures up to $500 Million in Non-Dilutive Financing From Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

THOMSON REUTERS
·
03 Apr

MoonLake Immunotherap Initiated at Outperform by RBC Capital

Dow Jones
·
18 Mar

RBC Capital Initiates a Buy Rating on MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
18 Mar

RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $17 Price Target

MT Newswires Live
·
18 Mar

MoonLake Immunotherapeutics: Promising Prospects for Sonelokimab in Inflammatory Diseases

TIPRANKS
·
12 Mar

MoonLake Immunotherap Is Maintained at Buy by Needham

Dow Jones
·
27 Feb

Moonlake Immunotherapeutics Faces Hurdles in Commercializing SLK Despite Potential Approvals

TIPRANKS
·
27 Feb

Buy Rating for MoonLake Immunotherapeutics Driven by Promising Clinical Programs and Market Potential

TIPRANKS
·
27 Feb

MoonLake Immunotherapeutics: Strong Buy Rating Amid Promising Phase 3 Trials and Robust Financial Position

TIPRANKS
·
27 Feb

Buy Rating for MoonLake Immunotherapeutics: Strong Financials and Promising Clinical Developments

TIPRANKS
·
27 Feb

MoonLake Immunotherapeutics: Promising Future with Strong Financial Position and Clinical Advancements

TIPRANKS
·
26 Feb

MoonLake Immunotherapeutics reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
26 Feb

MoonLake Immunotherapeutics Q4 Loss Widens

MT Newswires Live
·
26 Feb

MoonLake Q4 2024 GAAP EPS $(0.72) Misses $(0.60) Estimate, Year-end Cash, Cash Equivalents And Short-term Marketable Debt Securities Of $448M Expected To Providing Cash Runway To At Least The End Of 2026

Benzinga
·
26 Feb

Earnings Flash (MLTX) MoonLake Immunotherapeutics Posts Q4 Loss of $-0.72 a Share, vs. FactSet Est of $-0.59 Loss

MT Newswires Live
·
26 Feb